Published in

Oxford University Press, Open Forum Infectious Diseases, 1(6), 2018

DOI: 10.1093/ofid/ofy356

Links

Tools

Export citation

Search in Google Scholar

Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis

Journal article published in 2018 by Maria R. Ciardi ORCID, Marco Iannetta ORCID, Maria A. Zingaropoli ORCID, Romina Salpini ORCID, Marianna Aragri, Rosanna Annecca, Simona Pontecorvo ORCID, Marta Altieri, Gianluca Russo ORCID, Valentina Svicher ORCID, Claudio M. Mastroianni ORCID, Vincenzo Vullo ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
White circle
Published version: policy unclear
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients. More studies are needed to assess the optimal management of HBV reactivation in MS patients on ocrelizumab treatment.